Biora Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full-Year 2022 Financial ResultsGlobeNewsWire • 03/30/23
Biora Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 03/23/23
Biora Therapeutics Announces Bioavailability Results for Oral Delivery of GLP-1 Receptor AgonistGlobeNewsWire • 02/23/23
Biora Therapeutics Announces Improved Bioavailability Results for its Systemic Delivery PlatformGlobeNewsWire • 02/16/23
Biora Therapeutics, Inc. (BIOR) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?Zacks Investment Research • 02/02/23
Biora Therapeutics Presents Data from Device Performance Study with Repeat Doses in Both Fasted and Fed States at Crohn's & Colitis CongressGlobeNewsWire • 01/19/23
Biora Therapeutics Receives Pre-IND Feedback from FDA and Provides Update on Key Programs for 2023GlobeNewsWire • 01/09/23
Biora Therapeutics Announces Two Poster Presentations at the Crohn's & Colitis CongressGlobeNewsWire • 12/08/22
Biora Therapeutics Licenses Preeclampsia Rule-Out Test for Commercial DevelopmentGlobeNewsWire • 11/29/22
Biora Therapeutics, Inc. (BIOR) Reports Q3 Loss, Misses Revenue EstimatesZacks Investment Research • 11/14/22
Biora Therapeutics Provides Corporate Update and Reports Third Quarter 2022 Financial ResultsGlobeNewsWire • 11/14/22
Biora Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate UpdateGlobeNewsWire • 11/07/22
Biora Therapeutics Shares Data from Device Performance Study in Ulcerative Colitis PatientsGlobeNewsWire • 10/25/22
Biora Therapeutics Shares Five Posters Presented at American College of Gastroenterology Annual Scientific Meeting 2022GlobeNewsWire • 10/24/22
Biora Therapeutics Shares Preclinical Data on Oral Delivery of Biologics at the 2022 Parenteral Drug Association Universe of Pre-Filled Syringes and Injection Devices ConferenceGlobeNewsWire • 10/19/22
Biora Therapeutics to Participate in 12th Annual Partnership Opportunities in Drug Delivery ConferenceGlobeNewsWire • 10/10/22